Objective To examine the safety and tolerability of the antidepressant duloxetine across
multiple studies for major depressive disorder (MDD). Method Safety data were integrated …

OBJECTIVE: This analysis focuses on efficacy and safety data obtained from studies of
duloxetine for the treatment of major depressive disorder (MDD) within the approved dose …

Background Relationships between brain-derived neurotrophic factor (BDNF), interleukin
(IL)-6, and salivary cortisol and both depression severity and treatment response were …

Background: The comparative efficacy of selective serotonin reuptake inhibitors (SSRIs) and
serotoninnorepinephrine reuptake inhibitors (SNRIs) was recently debated. Meta-analyses …

The objective of this study was to determine whether the occurrence of discontinuation
symptoms was equivalent for abrupt discontinuation versus 1-week taper to desvenlafaxine …

Background: Most examinations of the clinical efficacy of drugs used to treat depression pool
subjects across gender and age groups. This investigation compared these patient …

Objectives: To evaluate the short-term efficacy and safety of desvenlafaxine (25–50 mg/d)
compared with placebo in children and adolescents with major depressive disorder (MDD) …

Introduction Mental health disorders, especially depressive and anxiety disorders, are
associated with substantial health-related burden. While the second-generation …

The combined serotonin–norepinephrine reuptake inhibitor, venlafaxine XR, has
demonstrated significant response and remission in patients diagnosed with depression …

Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Wyeth,
is a novel salt form of the isolated major active metabolite of the antidepressant venlafaxine …